Moreover, metformin, the primary drug for T2DM treatment, exhibits its efficacy by reducing IL-1β levels through NLRP3 inflammasome inhibition, thereby alleviating symptoms in patients. This evidence concerns the gene NLRP3 and type 2 diabetes mellitus.